Eli Lilly announced that it currently expects that its reported financial results calculated in accordance with U.S. generally accepted accounting principles and its non-GAAP financial results for the third quarter of 2024 will include acquired IPR&D charges of approximately $2.83B on a pre-tax basis, representing a charge of approximately $3.08 to both GAAP and non-GAAP earnings per share. “Lilly’s results for the quarter ended September 30, 2024, have not been finalized and are subject to Lilly’s financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimates described herein. As previously disclosed, while acquired IPR&D charges may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, Lilly does not forecast acquired IPR&D charges due to the uncertainty of the future occurrence, magnitude, and timing of these transactions in any given period,” the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- HIMS Stock Rises 208% in a Year and Is Ready to Compete with the Big Guns
- Pfizer (PFE) Faces Pressure after Activist Investor Starboard Acquires $1B Stake
- Trump backs off support of controversial drug pricing plan, STAT reports
- Hims & Hers falls after FDA says Lilly weight loss drug shortage is over
- End of weight loss shortage supports Lilly comments, says Deutsche Bank